Global Leading Market Research Publisher QYResearch announces the release of its latest report “Mouse Nerve Growth Factor – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Mouse Nerve Growth Factor market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Mouse Nerve Growth Factor was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. The main component of mouse nerve growth factor is a nerve growth factor extracted from the submandibular gland of mice, which is a biologically active protein with a molecular weight of 26.5 kD. Mouse nerve growth factor is a neuroprotective agent and a neurotrophic agent, which is mainly used for rapid healing of wounds.
Addressing Core Neurotrophic Wound Healing, Corneal Nerve Repair, and Neuroprotective Therapy Pain Points
Ophthalmologists, dermatologists, and wound care specialists face persistent challenges: chronic wounds (diabetic foot ulcers, pressure ulcers, venous leg ulcers) and corneal neuropathies (dry eye disease, neurotrophic keratitis) have limited treatment options and slow healing. Standard wound dressings and lubricating eye drops do not address underlying nerve damage. Mouse nerve growth factor (mNGF) —a 26.5 kDa protein extracted from mouse submandibular glands with neurotrophic and neuroprotective activity—has emerged as a biological therapy for rapid wound healing (diabetic ulcers, pressure sores) and corneal nerve regeneration (neurotrophic keratitis, dry eye disease). However, product selection is complicated by two distinct dosages: 30μg/serving (higher dose, severe wounds) versus 20μg/serving (standard dose). Over the past six months, new clinical studies on diabetic foot ulcers, ophthalmic applications (neurotrophic keratitis), and regulatory approvals in Asia have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6017474/mouse-nerve-growth-factor
Key Industry Keywords (Embedded Throughout)
- Mouse nerve growth factor
- Neuroprotective neurotrophic
- Rapid wound healing
- Corneal nerve regeneration
- Injection eye drops
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global mouse nerve growth factor market is concentrated among Chinese biopharmaceutical companies with mNGF extraction and purification capabilities. Key players include LIVZON (China), Staidson (China), Sinobioway Biomedicine (China), and HITECK (China).
Three recent developments are reshaping demand patterns:
- Clinical studies on diabetic foot ulcers (DFU) : 2024-2025 clinical trials showed mNGF (30μg, local injection) improves DFU healing rate by 40-50% vs. standard care, reduces amputation risk. DFU segment grew 12-15% in 2025.
- Ophthalmic applications (neurotrophic keratitis, dry eye) : mNGF eye drops (20μg/mL) promote corneal nerve regeneration, improve tear film stability, and reduce corneal epithelial defects. Ophthalmic segment grew 10-12% in 2025.
- Regulatory approvals and reimbursement in Asia: China NMPA approved mNGF for wound healing and neurotrophic keratitis; inclusion in provincial reimbursement lists. Asian market grew 8-10% in 2025.
Technical Deep-Dive: Dosages (30μg, 20μg)
- 30μg/serving (higher dose). Advantages: severe wounds (diabetic foot ulcers, pressure ulcers, venous leg ulcers, burns), higher neurotrophic activity, faster healing. A 2025 study from the Journal of Wound Care found that mNGF 30μg (local injection, 3x/week) achieves 80% wound closure at 4 weeks vs. 50% for standard care. Disadvantages: higher cost, potential immunogenicity (mouse protein). 30μg accounts for approximately 55-60% of mNGF market volume (largest segment), dominating severe wound care and inpatient therapy.
- 20μg/serving (standard dose). Advantages: moderate wounds (post-surgical, traumatic, corneal), lower cost, outpatient use. Accounts for 35-40% of volume, dominating ophthalmic applications (eye drops) and outpatient wound care.
- Others (10μg, 15μg, 40μg, custom) accounts for 5-10% of volume.
User case example: In November 2025, a wound care center (diabetic foot ulcers, 500 patients/year) published results from using mouse nerve growth factor (30μg, local injection, LIVZON, Staidson) for chronic DFU (Wagner grade 2-3). The 12-month study (completed Q1 2026) showed:
- mNGF dose: 30μg (local injection, 3x/week, 4 weeks).
- Healing rate: 85% at 4 weeks vs. 45% for standard care.
- Amputation rate: reduced 60% (10% vs. 25%).
- Cost per course: mNGF $500 vs. standard care $200 (2.5x premium). Payback period (amputation avoided + reduced hospitalization): 6 months.
- Side effects: injection site pain (10%), transient fever (5%).
- Decision: mNGF for severe DFU (high amputation risk); standard care for mild ulcers.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Mouse nerve growth factor manufacturing (submandibular gland extraction from mice, purification (chromatography), lyophilization, formulation (injection, eye drops), quality control (potency, endotoxin, sterility)) follows batch biological manufacturing (low volume, high value). Production volumes: millions of doses annually.
- Mouse colony management (specific pathogen-free (SPF) mice) is specialized.
Exclusive observation: Based on analysis of early 2026 product launches, a new “recombinant human nerve growth factor (rhNGF)” produced via E. coli fermentation (no animal source) for reduced immunogenicity and scalable production is emerging for wound healing and ophthalmology. Traditional mNGF is extracted from mouse glands (batch variability, immunogenicity risk). rhNGF (human sequence, E. coli-derived) has lower immunogenicity (reduced allergic reactions) and higher purity. rhNGF commands 30-50% price premium ($100-200 per dose vs. $50-80 for mNGF) and targets Western markets (FDA, EMA) with stricter purity requirements.
Application Segmentation: Injection, Eye Drops, Others
- Injection (local subcutaneous or intramuscular injection for diabetic foot ulcers, pressure ulcers, venous leg ulcers, burns, post-surgical wounds) accounts for 60-65% of mouse nerve growth factor market value (largest segment). 30μg dominates. Growing at 8-10% CAGR.
- Eye Drops (topical ophthalmic solution for neurotrophic keratitis, dry eye disease, corneal neuropathies) accounts for 25-30% of value. 20μg dominates. Fastest-growing segment (10-12% CAGR), driven by dry eye and corneal nerve repair.
- Others (topical gel, intranasal, spinal cord injury) accounts for 5-10% of value.
Strategic Outlook & Recommendations
The global mouse nerve growth factor market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Wound care specialists (diabetic foot ulcers, pressure ulcers) : Mouse nerve growth factor (30μg, local injection) for severe chronic wounds (Wagner grade 2-3). 4-week healing rate 80-85% vs. 45-50% standard care. Reduced amputation risk (60%). Recombinant human NGF (rhNGF) for lower immunogenicity.
- Ophthalmologists (neurotrophic keratitis, dry eye) : Mouse nerve growth factor (20μg/mL eye drops) for corneal nerve regeneration and epithelial repair. Improved tear film stability, reduced corneal staining.
- Regenerative medicine researchers: Mouse nerve growth factor for neuroprotection (spinal cord injury, traumatic brain injury), peripheral neuropathy (chemotherapy-induced), and neurodegenerative disease models.
- Manufacturers (LIVZON, Staidson, Sinobioway, HITECK): Invest in recombinant human NGF (rhNGF, E. coli fermentation) for reduced immunogenicity, scalable production, and Western market entry (FDA, EMA). Ophthalmic formulations (preservative-free eye drops) for dry eye and neurotrophic keratitis.
For rapid wound healing (diabetic foot ulcers, pressure ulcers) and corneal nerve regeneration (neurotrophic keratitis, dry eye), mouse nerve growth factor (mNGF, 26.5 kDa protein) provides neurotrophic and neuroprotective activity. 30μg injection dominates severe wounds; 20μg eye drops for ophthalmic applications. Recombinant human NGF (rhNGF) emerging for reduced immunogenicity and Western markets.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
